BiotechTube

Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd)

Phase 1/2Active
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Small-Cell Lung Cancer

Conditions

Small-Cell Lung Cancer, Neuroendocrine Carcinoma

Trial Timeline

Dec 14, 2020 → Jan 28, 2028

NCT ID
NCT04471727

About Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd)

Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd) is a phase 1/2 stage product being developed by Daiichi Sankyo for Small-Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04471727. Target conditions include Small-Cell Lung Cancer, Neuroendocrine Carcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04471727Phase 1/2Active

Competing Products

20 competing products in Small-Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Enzastaurin HCLEli LillyPhase 2
52
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
44
ALIMTA + CarboplatinEli LillyPhase 2
52
LazertinibYuhanPhase 1/2
41
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
CS-7017 + ErlotinibDaiichi SankyoPhase 1
33
Datopotamab Deruxtecan (Dato-DXd)Daiichi SankyoPhase 1/2
41
Raludotatug Deruxtecan + Ifinatamab Deruxtecan + Docetetaxel + 5-hydroxytryptamine subtype 3 receptor antagonist + Neurokinin-1 receptor antagonist + CorticosteroidDaiichi SankyoPhase 2
52
Pembrolizumab + Carboplatin + Paclitaxel + Pemetrexed + Vibostolimab + Boserolimab + MK-4830 + MK-0482 + Ifinatamab Deruxtecan (I-DXd) + HER3-DXdDaiichi SankyoPhase 1/2
41
CS-7017 + Carboplatin + PaclitaxelDaiichi SankyoPhase 1
33
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Gilteritinib + ErlotinibAstellas PharmaPhase 1/2
41
naquotinib + midazolamAstellas PharmaPhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85